PharmacologyvnNCLEXvnQuestions
Avnnewlyvnadmittedvnclientvntakesvndigoxinvn0.25vnmg/day.vnThevnnursevnkno
wsvnthatvnwhichvnisvnthevnserumvntherapeuticvnrangevnforvndigoxin?
a.vn0.1vntovn1.5vnng/mL
b.vn0.5vntovn2.0vnng/mL
c.vn1.0vntovn2.5vnng/mL
d.vn2.0vntovn4.0vnng/mLvn-vncorrectvnanswer✔ ✔ b.vn0.5vntovn2.0vnng/mL
Thevnclient'svnserumvndigoxinvnlevelvnisvn3.0vnng/mL.vnWhatvndoesvnthevnnursev
nknowvnaboutvnthisvnserumvndigoxinvnlevel?
a.vnItvnisvninvnthevnhighvn(elevated)vnrange.
b.vnItvnisvninvnthevnlowvn(decreased)vnrange.
c.vnItvnisvnwithinvnthevnnormalvnrange.
d.vnItvnisvninvnthevnlowvnaveragevnrange.vn-vncorrectvnanswer✔ ✔
a.vnItvnisvninvnthevnhighvn(elevated)vnrange.
Thevnnursevnisvnassessingvnthevnclientvnforvnpossiblevnevidencevnofvndigitalisvnto
xicity.vnThevnnursevnacknowledgesvnthatvnwhichvnisvnincludedvninvnthevnsignsvn
andvnsymptomsvnforvndigitalisvntoxicity?
,a.vnPulsevn(heart)vnratevnofvn100vnbeats/min
b.vnPulsevnofvn72vnwithvnanvnirregularvnrate
c.vnPulsevngreatervnthanvn60vnbeats/minvnandvnirregularvnrate
d.vnPulsevnbelowvn60vnbeats/minvnandvnirregularvnratevn-vncorrectvnanswer✔
✔ d.vnPulsevnbelowvn60vnbeats/minvnandvnirregularvnrate
Thevnclientvnisvnalsovntakingvnavndiureticvnthatvndecreasesvnhervnpotassiumvnleve
l.vnThevnnursevnexpectsvnthatvnavnlowvnpotassiumvnlevelvn(hypokalemia)vncould
vnhavevnwhatvneffectvnonvnthevndigoxin?
a.vnIncreasevnthevnserumvndigoxinvnsensitivityvnlevel
b.vnDecreasevnthevnserumvndigoxinvnsensitivityvnlevel
c.vnNotvnhavevnanyvneffectvnonvnthevnserumvndigoxinvnsensitivityvnlevel
d.vnCausevnavnlowvnaveragevnserumvndigoxinvnsensitivityvnlevelvn-
vncorrectvnanswer✔ ✔
a.vnIncreasevnthevnserumvndigoxinvnsensitivityvnlevel
Whenvnavnclientvnfirstvntakesvnavnnitrate,vnthevnnursevnexpectsvnwhichvnsympto
mvnthatvnoftenvnoccurs?
a.vnNauseavnandvnvomiting
,b.vnHeadaches
c.vnStomachvncramps
d.vnIrregularvnpulsevnratevn-vncorrectvnanswer✔ ✔ b.vnHeadaches
Thevnnursevnacknowledgesvnthatvnbetavnblockersvnarevnasvneffectivevnasvnantian
ginalsvnbecausevntheyvndovnwhat?
a.vnIncreasevnoxygenvntovnthevnsystemicvncirculation.
b.vnMaintainvnheartvnratevnandvnbloodvnpressure.
c.vnDecreasevnheartvnratevnandvndecreasevnmyocardialvncontractility.
d.vnDecreasevnheartvnratevnandvnincreasevnmyocardialvncontractility.vn-
vncorrectvnanswer✔ ✔
c.vnDecreasevnheartvnratevnandvndecreasevnmyocardialvncontractility.
Thevnhealthvncarevnprovidervnisvnplanningvntovndiscontinuevnavnclient'svnbetavnbl
ocker.vnWhatvninstructionvnshouldvnthevnnursevngivevnthevnclientvnregardingvnth
evnbetavnblocker?
a.vnThevnbetavnblockervnshouldvnbevnabruptlyvnstoppedvnwhenvnanothervncardia
cvndrugvnisvnprescribed.
b.vnThevnbetavnblockervnshouldvnNOTvnbevnabruptlyvnstopped;vnthevndosevnshou
ldvnbevntaperedvndown.
, c.vnThevnbetavnblockervndosevnshouldvnbevnmaintainedvnwhilevntakingvnanotherv
nantianginalvndrug.
d.vnHalfvnthevnbetavnblockervndosevnshouldvnbevntakenvnforvnthevnnextvnseveralvn
weeks.vn-vncorrectvnanswer✔ ✔
b.vnThevnbetavnblockervnshouldvnNOTvnbevnabruptlyvnstopped;vnthevndosevnsh
ouldvnbevntaperedvndown.
Thevnbetavnblockervnacebutololvn(Sectral)vnisvnprescribedvnforvndysrhythmias.v
nThevnnursevnknowsvnthatvnwhatvnisvnthevnprimaryvnpurposevnofvnthevndrug?
a.vnTovnincreasevnthevnbeta1vnandvnbeta2vnreceptorsvninvnthevncardiacvntissues
b.vnTovnincreasevnthevnflowvnofvnoxygenvntovnthevncardiacvntissues
c.vnTovnblockvnthevnbeta1-adrenergicvnreceptorsvninvnthevncardiacvntissues
d.vnTovnblockvnthevnbeta2-adrenergicvnreceptorsvninvnthevncardiacvntissuesvn-
vncorrectvnanswer✔ ✔ c.vnTovnblockvnthevnbeta1-
adrenergicvnreceptorsvninvnthevncardiacvntissues
Avnclientvnisvntovnbevndischargedvnhomevnwithvnavntransdermalvnnitroglycerinvn
patch.vnWhichvninstructionvnwillvnthevnnursevnincludevninvnthevnclient'svnteachi
ngvnplan?
a.vn"Applyvnthevnpatchvntovnavnnonhairyvnareavnofvnthevnuppervntorsovnorvnarm."
b.vn"Applyvnthevnpatchvntovnthevnsamevnsitevneachvnday."
Avnnewlyvnadmittedvnclientvntakesvndigoxinvn0.25vnmg/day.vnThevnnursevnkno
wsvnthatvnwhichvnisvnthevnserumvntherapeuticvnrangevnforvndigoxin?
a.vn0.1vntovn1.5vnng/mL
b.vn0.5vntovn2.0vnng/mL
c.vn1.0vntovn2.5vnng/mL
d.vn2.0vntovn4.0vnng/mLvn-vncorrectvnanswer✔ ✔ b.vn0.5vntovn2.0vnng/mL
Thevnclient'svnserumvndigoxinvnlevelvnisvn3.0vnng/mL.vnWhatvndoesvnthevnnursev
nknowvnaboutvnthisvnserumvndigoxinvnlevel?
a.vnItvnisvninvnthevnhighvn(elevated)vnrange.
b.vnItvnisvninvnthevnlowvn(decreased)vnrange.
c.vnItvnisvnwithinvnthevnnormalvnrange.
d.vnItvnisvninvnthevnlowvnaveragevnrange.vn-vncorrectvnanswer✔ ✔
a.vnItvnisvninvnthevnhighvn(elevated)vnrange.
Thevnnursevnisvnassessingvnthevnclientvnforvnpossiblevnevidencevnofvndigitalisvnto
xicity.vnThevnnursevnacknowledgesvnthatvnwhichvnisvnincludedvninvnthevnsignsvn
andvnsymptomsvnforvndigitalisvntoxicity?
,a.vnPulsevn(heart)vnratevnofvn100vnbeats/min
b.vnPulsevnofvn72vnwithvnanvnirregularvnrate
c.vnPulsevngreatervnthanvn60vnbeats/minvnandvnirregularvnrate
d.vnPulsevnbelowvn60vnbeats/minvnandvnirregularvnratevn-vncorrectvnanswer✔
✔ d.vnPulsevnbelowvn60vnbeats/minvnandvnirregularvnrate
Thevnclientvnisvnalsovntakingvnavndiureticvnthatvndecreasesvnhervnpotassiumvnleve
l.vnThevnnursevnexpectsvnthatvnavnlowvnpotassiumvnlevelvn(hypokalemia)vncould
vnhavevnwhatvneffectvnonvnthevndigoxin?
a.vnIncreasevnthevnserumvndigoxinvnsensitivityvnlevel
b.vnDecreasevnthevnserumvndigoxinvnsensitivityvnlevel
c.vnNotvnhavevnanyvneffectvnonvnthevnserumvndigoxinvnsensitivityvnlevel
d.vnCausevnavnlowvnaveragevnserumvndigoxinvnsensitivityvnlevelvn-
vncorrectvnanswer✔ ✔
a.vnIncreasevnthevnserumvndigoxinvnsensitivityvnlevel
Whenvnavnclientvnfirstvntakesvnavnnitrate,vnthevnnursevnexpectsvnwhichvnsympto
mvnthatvnoftenvnoccurs?
a.vnNauseavnandvnvomiting
,b.vnHeadaches
c.vnStomachvncramps
d.vnIrregularvnpulsevnratevn-vncorrectvnanswer✔ ✔ b.vnHeadaches
Thevnnursevnacknowledgesvnthatvnbetavnblockersvnarevnasvneffectivevnasvnantian
ginalsvnbecausevntheyvndovnwhat?
a.vnIncreasevnoxygenvntovnthevnsystemicvncirculation.
b.vnMaintainvnheartvnratevnandvnbloodvnpressure.
c.vnDecreasevnheartvnratevnandvndecreasevnmyocardialvncontractility.
d.vnDecreasevnheartvnratevnandvnincreasevnmyocardialvncontractility.vn-
vncorrectvnanswer✔ ✔
c.vnDecreasevnheartvnratevnandvndecreasevnmyocardialvncontractility.
Thevnhealthvncarevnprovidervnisvnplanningvntovndiscontinuevnavnclient'svnbetavnbl
ocker.vnWhatvninstructionvnshouldvnthevnnursevngivevnthevnclientvnregardingvnth
evnbetavnblocker?
a.vnThevnbetavnblockervnshouldvnbevnabruptlyvnstoppedvnwhenvnanothervncardia
cvndrugvnisvnprescribed.
b.vnThevnbetavnblockervnshouldvnNOTvnbevnabruptlyvnstopped;vnthevndosevnshou
ldvnbevntaperedvndown.
, c.vnThevnbetavnblockervndosevnshouldvnbevnmaintainedvnwhilevntakingvnanotherv
nantianginalvndrug.
d.vnHalfvnthevnbetavnblockervndosevnshouldvnbevntakenvnforvnthevnnextvnseveralvn
weeks.vn-vncorrectvnanswer✔ ✔
b.vnThevnbetavnblockervnshouldvnNOTvnbevnabruptlyvnstopped;vnthevndosevnsh
ouldvnbevntaperedvndown.
Thevnbetavnblockervnacebutololvn(Sectral)vnisvnprescribedvnforvndysrhythmias.v
nThevnnursevnknowsvnthatvnwhatvnisvnthevnprimaryvnpurposevnofvnthevndrug?
a.vnTovnincreasevnthevnbeta1vnandvnbeta2vnreceptorsvninvnthevncardiacvntissues
b.vnTovnincreasevnthevnflowvnofvnoxygenvntovnthevncardiacvntissues
c.vnTovnblockvnthevnbeta1-adrenergicvnreceptorsvninvnthevncardiacvntissues
d.vnTovnblockvnthevnbeta2-adrenergicvnreceptorsvninvnthevncardiacvntissuesvn-
vncorrectvnanswer✔ ✔ c.vnTovnblockvnthevnbeta1-
adrenergicvnreceptorsvninvnthevncardiacvntissues
Avnclientvnisvntovnbevndischargedvnhomevnwithvnavntransdermalvnnitroglycerinvn
patch.vnWhichvninstructionvnwillvnthevnnursevnincludevninvnthevnclient'svnteachi
ngvnplan?
a.vn"Applyvnthevnpatchvntovnavnnonhairyvnareavnofvnthevnuppervntorsovnorvnarm."
b.vn"Applyvnthevnpatchvntovnthevnsamevnsitevneachvnday."
